Mar 13 |
Jefferies starts Cue at buy, cites partnering potential
|
Feb 29 |
Cue Biopharma’s Lead Clinical Asset, CUE-101, to be Featured at the 2024 Multi-disciplinary Head and Neck Cancers Symposium
|
Feb 27 |
Strength Seen in Precision BioSciences (DTIL): Can Its 20.4% Jump Turn into More Strength?
|
Jan 17 |
Cue Biopharma (NASDAQ:CUE) investors are sitting on a loss of 80% if they invested three years ago
|
Jan 9 |
Cue Biopharma: Not Exactly Sinking The Money Ball Yet
|
Dec 7 |
Are Medical Stocks Lagging Corvus Pharmaceuticals (CRVS) This Year?
|
Nov 9 |
Cue Biopharma reports Q3 results
|
Nov 9 |
Cue Biopharma Reports Third Quarter 2023 Financial Results and Recent Business Highlights
|
Nov 7 |
Cue Biopharma to Present at Three Upcoming Investor Healthcare Conferences in November
|
Nov 3 |
Cue Biopharma Presents New Positive Data from Phase 1 Trials of CUE-101 in Head and Neck Cancer and CUE-102 in Wilms’ Tumor 1 Positive Cancers at SITC 2023
|